International Journal of OncologyEisinger F, Charafe-Jauffret E, Jacquemier J, et al: Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: Computed efficacy, effectiveness and impact. Int J Oncol 18:5-10, 2001
"It has been known for quite some time, and previous data have shown that even someone who delays starting their tamoxifen, say a year or two out, still derives benefit," he toldMedscape Medical News. The South Swedish and South-East Swedish Breast Cancer Groups conducted the randomized phas...
Intervention Study (IBIS-I) showed that tamoxifen produced a 32% reduction in the risk of invasive estrogen receptor (ER)-positive tumors in women who were at increased risk of breast cancer; however, this came at the expense of an increase in the rates of thrombo- embolic and other events...
Context Among cancer-free women aged 35 years or older, tamoxifen reduced the incidence of estrogen receptor (ER)–positive but not ER-negative breast cancer. The effect of tamoxifen on breast cancer incidence among women at extremely high risk due to inherited BRCA1 or BRCA2 mutations is unkno...
Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P... OBJECTIVE: To evaluate the effect of tamoxifen on incidence of breast cancer among cancer-free women with inherited BRCA1 or BRCA2 ...
If validated, morphological and molecular markers could eventually replace cancer incidence as an indicator of efficacy in future phase III trials.doi:10.1186/bcr279Carol J FabianBioMed CentralBreast Cancer ResearchFabian C J.Breast cancer chemoprevention: beyond tamoxifen. Breast cancer research : BCR ...
Breast Cancer Deaths Decline Tamoxifen Gets Most of the CreditLONDON -- Better treatment over the last decade has slashed breast cancer death rates in the United States and Britain and will save the lives of 14,000 women this year in the two countries, new research shows.U.S. Newspapers...
The lifesaving benefit of taking tamoxifen to treat early breast cancer lasts for at least a decade, but only if the drug is used for five years and no longer, two studies showed.
Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsRadiotherapy... LE Rutqvist,B Cedermark,U Glas,....
Tamoxifen (TAM) is known to have a dual mechanism of action: (1) to compete with 17β-estradiol (E2) at the receptor site and to block the promotional role of E2 in breast cancer; and (2) to bind DNA after metabolic activation and to initiate carcinogenesis. Recent large clinical ...